0001093557-20-000129.txt : 20200417 0001093557-20-000129.hdr.sgml : 20200417 20200417180435 ACCESSION NUMBER: 0001093557-20-000129 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200415 FILED AS OF DATE: 20200417 DATE AS OF CHANGE: 20200417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Balo Andrew K CENTRAL INDEX KEY: 0001323190 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 20800797 MAIL ADDRESS: STREET 1: C/O DEXCOM, INC. STREET 2: 5555 OBERLIN DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-04-15 0 0001093557 DEXCOM INC DXCM 0001323190 Balo Andrew K 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 0 1 0 0 * Common Stock 2020-04-15 4 S 0 1032 279.3273 D 57556 D Common Stock 2020-04-15 4 S 0 1382 281.0976 D 56174 D Common Stock 2020-04-15 4 S 0 1110 284.1945 D 55064 D Common Stock 2020-04-15 4 S 0 2385 285.1425 D 52679 D Common Stock 2020-04-15 4 S 0 730 286.2411 D 51949 D Common Stock 2020-04-15 4 S 0 51 287.75 D 51898 D On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. This transaction was executed in multiple trades at prices ranging from $278.90 to $279.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. This transaction was executed in multiple trades at prices ranging from $280.88 to $281.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $283.73 to $284.70. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $284.77 to $285.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $285.88 to $286.85. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. *EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development By: Jereme Sylvain For: Andrew K Balo 2020-04-17